Last reviewed · How we verify
TLL018 tablets
TLL018 tablets is a Small molecule drug developed by Hangzhou Highlightll Pharmaceutical Co., Ltd. It is currently in Phase 2 development. Also known as: TLL018 Placeboes.
TLL018 tablets are small molecule tablets used in clinical trials for conditions such as Chronic Spontaneous Urticaria, Plaque Psoriasis, and Rheumatoid Arthritis. The exact mechanism of action of TLL018 tablets is currently unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TLL018 tablets |
|---|---|
| Also known as | TLL018 Placeboes |
| Sponsor | Hangzhou Highlightll Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis (PHASE3)
- A Study of Efficacy and Safety of TLL-018 in CSU Participants (PHASE3)
- The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis (PHASE2)
- Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. (PHASE1)
- Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects (PHASE1)
- A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs (PHASE3)
- Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis (PHASE1)
- The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TLL018 tablets CI brief — competitive landscape report
- TLL018 tablets updates RSS · CI watch RSS
- Hangzhou Highlightll Pharmaceutical Co., Ltd portfolio CI
Frequently asked questions about TLL018 tablets
What is TLL018 tablets?
Who makes TLL018 tablets?
Is TLL018 tablets also known as anything else?
What development phase is TLL018 tablets in?
Related
- Manufacturer: Hangzhou Highlightll Pharmaceutical Co., Ltd — full pipeline
- Also known as: TLL018 Placeboes
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing